MNA
GMAB icon

Manning & Napier Advisors’s Genmab GMAB Stock Holding History

Manning & Napier Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22K Sell
47
-7
-13% -$186 ﹤0.01% 797
2026
Q1 		$1.4K Sell
54
-18
-25% -$539 ﹤0.01% 569
2025
Q4 		$2.27K Buy
+72
New +$2.24K ﹤0.01% 483

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Manning & Napier Advisors's GMAB Position: Q2 2026 in Review

Manning & Napier Advisors reduced its Genmab (GMAB) stake by 13% in Q2 2026, selling an estimated $186 and leaving 47 shares worth $1.22K. The position accounts for ﹤0.01% of the portfolio, ranked #797.

Manning & Napier Advisors first reported a position in GMAB in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.27K in Q4 2025. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Manning & Napier Advisors held 47 shares of Genmab worth $1.22K as of Q2 2026.
  • Manning & Napier Advisors sold 7 Genmab shares in Q2 2026, an estimated $186.
  • Genmab made up ﹤0.01% of Manning & Napier Advisors's portfolio in Q2 2026, its #797 holding.
  • Manning & Napier Advisors first reported a position in Genmab in Q4 2025 and has held it in 3 quarters since.
  • Manning & Napier Advisors's Genmab position peaked at $2.27K in Q4 2025.
  • 290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Manning & Napier Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.